Motivational Interviewing for COVID-19 Vaccination Acceptance

(G2YMI Trial)

Overseen By Emerson Delacroix, M.A.C.P.

Age: 18+

Sex: Any

Trial Phase: Academic

Sponsor: University of Michigan

Disqualifiers: Under 18, Unwilling to consent, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: Unknown

700 Participants Needed

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial uses community-focused methods to encourage COVID-19 vaccination among African American and Latinx communities in specific Michigan counties. By understanding and addressing vaccine hesitancy through local engagement, the study aims to increase vaccination rates in these disproportionately affected groups.

Do I have to stop taking my current medications for this trial?

The trial information does not specify whether you need to stop taking your current medications.

Is motivational interviewing safe for use in humans?

Motivational interviewing is a communication technique used by healthcare professionals to help people make informed decisions, and it is generally considered safe for use in humans. ^{1 2 3 4 5}

How does the treatment Motivational Interviewing based SMS/MMS and web content differ from other treatments for COVID-19 vaccine hesitancy?

This treatment is unique because it uses motivational interviewing techniques delivered through SMS/MMS and web content to address COVID-19 vaccine hesitancy. Unlike traditional methods, it focuses on enhancing personal motivation and resolving ambivalence about vaccination through patient-centered communication, making it a novel approach in encouraging vaccine acceptance. ^{1 2 3 4 5}

What data supports the effectiveness of the treatment Motivational Interviewing based SMS/MMS and web content for COVID-19 vaccination acceptance?

Motivational interviewing, a communication style that helps people explore and resolve their mixed feelings, has been shown to help healthcare professionals reduce COVID-19 vaccine hesitancy by enabling informed decision-making. This approach emphasizes collaboration and understanding, which can be effective in addressing vaccine hesitancy. ^{1 2 5 6 7}

Who Is on the Research Team?

Emerson Delacroix, M.A.C.P.

Principal Investigator

University of Michigan

Ken Resnicow, Ph.D.

Principal Investigator

University of Michigan

Erica Marsh, M.D.

Principal Investigator

University of Michigan - Michigan Medicine

Are You a Good Fit for This Trial?

This trial is for adults over 18 in Michigan, particularly from African American and Latinx communities, who are vaccinated and boosted but want to help others get vaccinated (Champions), or those unvaccinated/unboosted willing to participate. They must be able to use SMS/MMS and read/write in English or Spanish.

Inclusion Criteria

I am over 18 and have not received all my COVID-19 vaccinations or boosters.

I am over 18, vaccinated, and boosted, and want to be a Champion.

Must be able to receive SMS/MMS/text messages

Exclusion Criteria

I am willing to complete communication training in English.

I am under 18 years old.

Unwilling to consent

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Intervention

Participants receive Motivational Interviewing based SMS/MMS messages to increase COVID-19 vaccine uptake and complete Baseline and Follow-up surveys

6 months

Baseline and Follow-up surveys

Follow-up

Participants are monitored for changes in vaccine uptake intentions and self-reported vaccine uptake

6 months

What Are the Treatments Tested in This Trial?

Interventions

• Motivational Interviewing based SMS/MMS and web content
• Motivational Interviewing of SMS and web content

Trial Overview The study tests motivational interviewing via text messages and web content designed to increase COVID-19 vaccine uptake among groups facing disparities. It's based on community feedback within four Michigan counties with a history of lower vaccination rates.

How Is the Trial Designed?

Group I: Intervention Experimental Treatment 1 Intervention

Enrolled study participants receive Motivational Interviewing based SMS/MMS messages to increase COVID-19 vaccine uptake, and complete Baseline and Follow-up surveys.

Group II: Control Active Control 1 Intervention

Enrolled study participants receive a simple website and complete a Baseline and Follow-up survey, after which they will receive the interventional Motivational Interviewing based SMS/MMS messages to increase COVID-19 vaccine uptake.

Who Is Running the Clinical Trial?

University of Michigan

Lead Sponsor

Trials

1,891

Recruited

6,458,000+

National Institutes of Health (NIH)

Collaborator

Trials

2,896

Recruited

8,053,000+

National Institute on Minority Health and Health Disparities (NIMHD)

Collaborator

Trials

473

Recruited

1,374,000+

Citations

1. United States pubmed.ncbi.nlm.nih.gov

Using Technology to Overcome Vaccine Hesitancy. [2023]

2. Netherlands pubmed.ncbi.nlm.nih.gov

Using motivational interviewing techniques to inform decision-making for COVID-19 vaccination. [2021]

3. United States pubmed.ncbi.nlm.nih.gov

Improving Conversations With COVID-19 Vaccine Hesitant Patients: Action Research to Support Family Physicians. [2022]

4. United States pubmed.ncbi.nlm.nih.gov

Developing and testing a COVID-19 vaccination acceptance intervention: A pragmatic trial comparing vaccine acceptance intervention vs usual care - Rationale, methods, and implementation. [2023]

5. United States pubmed.ncbi.nlm.nih.gov

Motivational Interviewing Strategies for Addressing COVID-19 Vaccine Hesitancy. [2022]

6. United States pubmed.ncbi.nlm.nih.gov

The use of motivational interviewing to overcome COVID-19 vaccine hesitancy in primary care settings. [2023]

7. United States pubmed.ncbi.nlm.nih.gov

Motivational interview-based health mediator interventions increase intent to vaccinate among disadvantaged individuals. [2023]